Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations
- PMID: 36830922
- PMCID: PMC9953187
- DOI: 10.3390/biomedicines11020385
Clinical and Therapeutic Evaluation of the Ten Most Prevalent CRB1 Mutations
Abstract
Mutations in the Crumbs homolog 1 (CRB1) gene lead to severe inherited retinal dystrophies (IRDs), accounting for nearly 80,000 cases worldwide. To date, there is no therapeutic option for patients suffering from CRB1-IRDs. Therefore, it is of great interest to evaluate gene editing strategies capable of correcting CRB1 mutations. A retrospective chart review was conducted on ten patients demonstrating one or two of the top ten most prevalent CRB1 mutations and receiving care at Columbia University Irving Medical Center, New York, NY, USA. Patient phenotypes were consistent with previously published data for individual CRB1 mutations. To identify the optimal gene editing strategy for these ten mutations, base and prime editing designs were evaluated. For base editing, we adopted the use of a near-PAMless Cas9 (SpRY Cas9), whereas for prime editing, we evaluated the canonical NGG and NGA prime editors. We demonstrate that for the correction of c.2843G>A, p.(Cys948Tyr), the most prevalent CRB1 mutation, base editing has the potential to generate harmful bystanders. Prime editing, however, avoids these bystanders, highlighting its future potential to halt CRB1-mediated disease progression. Additional studies investigating prime editing for CRB1-IRDs are needed, as well as a thorough analysis of prime editing's application, efficiency, and safety in the retina.
Keywords: CRISPR; Crumbs homolog 1 (CRB1); Leber Congenital Amaurosis (LCA); base editing; inherited retinal disease (IRD); maculopathy; prime editing; retinitis pigmentosa.
Conflict of interest statement
Stephen H. Tsang receives financial support from Abeona Therapeutics, Inc and Emendo. He is also the founder of Rejuvitas and is on the scientific and clinical advisory board for Nanoscope Therapeutics. Peter M.J. Quinn receives research support from Rejuvitas, Inc. Columbia University has filed patent applications related to this work for which Bruna Lopes da Costa, Stephen H. Tsang., and Peter M.J. Quinn are listed as inventors.
Figures
References
-
- Stone E.M., Andorf J.L., Whitmore S.S., DeLuca A.P., Giacalone J.C., Streb L.M., Braun T.A., Mullins R.F., Scheetz T.E., Sheffield V.C., et al. Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease. Ophthalmology. 2017;124:1314–1331. doi: 10.1016/j.ophtha.2017.04.008. - DOI - PMC - PubMed
-
- Talib M., van Schooneveld M.J., van Genderen M.M., Wijnholds J., Florijn R.J., ten Brink J.B., Schalij-Delfos N.E., Dagnelie G., Cremers F.P.M., Wolterbeek R., et al. Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study. Ophthalmology. 2017;124:884–895. doi: 10.1016/j.ophtha.2017.01.047. - DOI - PubMed
-
- Den Hollander A.I., ten Brink J.B., de Kok Y.J., van Soest S., van den Born L.I., van Driel M.A., van de Pol D.J., Payne A.M., Bhattacharya S.S., Kellner U., et al. Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12) Nat. Genet. 1999;23:217–221. doi: 10.1038/13848. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
